Readers of this space know that the investment bias is toward large-cap companies with demonstrated business models, who have a competitive advantage in established markets, preferably with a favorable, global trend as a support. And with that in mind, Johnson & Johnson (NYSE: JNJ) is worth a review.The value proposition with Johnson & Johnson 'isn't rocket science,' as they say, even though the business model (obviously) involves a considerable amount of science.
Tax Reform in This Election Year: It's Not Likely
Which Credit Card Rewards Does the IRS Care About?

